Scarica l'app Stockscreener
1.18
7.27%
0.08
Pre-mercato:
1.28
0.10
+8.47%
Precedente Chiudi:
$1.10
Aprire:
$1.21
Volume 24 ore:
1.58M
Relative Volume:
4.33
Capitalizzazione di mercato:
$26.39M
Reddito:
-
Utile/perdita netta:
$-16.51M
Rapporto P/E:
-0.8723
EPS:
-1.3528
Flusso di cassa netto:
$-15.68M
1 W Prestazione:
+24.21%
1M Prestazione:
-15.11%
6M Prestazione:
-41.00%
1 anno Prestazione:
-70.20%
Intervallo 1D:
$1.12
$1.3896
Intervallo di 1 settimana:
$0.9174
$1.3896
Portata 52W:
$0.9174
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
Nome
Medicus Pharma Ltd
Settore
Industria
Telefono
610-540-7515
Indirizzo
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
1.18 | 24.60M | 0 | -16.51M | -15.68M | -1.3528 |
|
LLY
Lilly Eli Co
|
1,020.56 | 977.37B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
244.99 | 586.40B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
228.72 | 411.55B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
208.67 | 324.75B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
165.38 | 317.08B | 54.72B | 14.02B | 15.32B | 7.1855 |
Medicus Pharma Ltd Borsa (MDCX) Ultime notizie
Reliant AI Partnership Targets Faster, More Efficient Clinical Trials - TipRanks
Reliant AI Partnership Targets Faster, More Efficient Clinical Trials With Medicus Pharma - TipRanks
Medicus Pharma on Bloomberg World - The Florida Times-Union
Medicus Pharma Receives FDA Clearance to Begin Phase 2b Teverelix Study - MyChesCo
Is Medicus Pharma Ltd. Equity Warrant vulnerable to short sellersShare Buyback & Stepwise Trade Execution Plans - mfd.ru
Can Medicus Pharma Ltd. sustain its profitability2025 Growth vs Value & Weekly Top Gainers Alerts - mfd.ru
Does Medicus Pharma Ltd. Equity Warrant have declining or rising EPS2025 Support & Resistance & Fast Entry High Yield Stock Tips - mfd.ru
Medicus Pharma’s Teverelix Phase 2b trial cleared by FDAICYMI - Proactive financial news
Can Medicus Pharma Ltd. Equity Warrant ride the EV waveWeekly Market Outlook & Short-Term High Return Ideas - mfd.ru
Aug Reactions: Is Medicus Pharma Ltd Equity Warrant subject to activist investor interestEarnings Performance Report & High Win Rate Trade Tips - baoquankhu1.vn
Is Medicus Pharma Ltd. Equity Warrant a speculative investmentGold Moves & Low Volatility Stock Suggestions - mfd.ru
Will Medicus Pharma Ltd. Equity Warrant benefit from rising consumer demand2025 Top Decliners & Comprehensive Market Scan Insights - mfd.ru
Why Medicus Pharma Ltd. stock attracts high net worth investorsDollar Strength & High Win Rate Trade Alerts - mfd.ru
Aug Decliners: Is Medicus Pharma Ltd Equity Warrant likely to announce a buybackMarket Trend Review & Short-Term High Return Strategies - baoquankhu1.vn
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement - Asbury Park Press
Analyst Calls: Can Medicus Pharma Ltd stock outperform in a bear marketSell Signal & AI Enhanced Trading Alerts - baoquankhu1.vn
Will Medicus Pharma Ltd. (N460) stock sustain bullish trend into 20252025 AllTime Highs & Short-Term Trading Opportunity Alerts - mfd.ru
Medicus Pharma cleared to launch Phase 2b Teverelix study in Prostate Cancer - Proactive financial news
Medicus Pharma Partners With Gorlin Syndrome Alliance to Expand Access to SKINJECT - MSN
Is Medicus Pharma Ltd. Equity Warrant forming bullish engulfing patterns2025 Key Highlights & Trade Opportunity Analysis - mfd.ru
Is Medicus Pharma Ltd. Equity Warrant affected by consumer sentimentTrade Entry Summary & Fast Momentum Entry Tips - mfd.ru
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - PhillyBurbs
Can Medicus Pharma Ltd. expand its profit margins2025 Analyst Calls & Long-Term Investment Growth Plans - mfd.ru
What are Medicus Pharma Ltd. Equity Warrant’s technical support levels2025 Breakouts & Breakdowns & AI Powered Trade Plan Recommendations - mfd.ru
FDA clears Medicus Pharma’s prostate cancer drug for phase 2b trial - Investing.com South Africa
FDA Clears Medicus to Advance Prostate Cancer Drug Aimed at Heart-Risk Patients - MyChesCo
New to The Street Signs Six-Part Media Series Featuring Medicus Pharma Ltd. - USA Today
Small cap wrap: Medicus Pharma, 1911 Gold, NanoViricides, Nextech3D.ai, NextSource Materials… - Proactive financial news
Medicus Pharma Wins FDA Go-Ahead for Phase 2b Teverelix Trial in High-Risk Prostate Cancer - TipRanks
Medicus Pharma receives FDA clearance to proceed with Phase 2b prostate cancer study - Yahoo Finance
Medicus Pharma Receives FDA 'Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk - The Manila Times
Medicus Pharma Receives FDA “Study May Proceed” Clearance - GlobeNewswire
How Medicus Pharma Ltd. Equity Warrant stock reacts to inflationary pressures2025 Support & Resistance & Momentum Based Trading Ideas - mfd.ru
Trade Report: Can Medicus Pharma Ltd expand its profit marginsJuly 2025 Review & Risk Managed Trade Strategies - baoquankhu1.vn
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform - The Marion Star
Merger Talk: Can Medicus Pharma Ltd expand its profit marginsTrade Entry Summary & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Medicus Pharma Ltd Azioni (MDCX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):